Genprex, Inc 8-K, filed Dec 19, 2022
Genprex, Inc. (GNPX)
8-K
2022-12-19
For: 2022-12-12
View Original
Added on
April 12, 2026
About this 8-K
Genprex, Inc filed this 8-K on December 19, 2022, reporting on events of December 12, 2022.
Items reported
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or other jurisdiction of
incorporation or organization)
|
(Commission File Number)
|
(I.R.S. Employer
Identification Number)
|
|
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (512 ) 537-7997
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange on which registered
|
||
|
|
|
The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item 8.01 Other Events.
On December 12, 2022, the Safety Review Committee for the Acclaim-1 Phase 1/2 clinical trial that uses a combination of Genprex, Inc.’s REQORSA® and AstraZeneca PLC’s Tagrisso® in patients with late-stage non-small cell lung cancer that has activating epidermal growth factor receptor (EGFR”) mutations and progression after treatment with Tagrisso, approved escalating the dose in the Phase 1 dose escalation portion of the study from 0.09 mg/kg in the second cohort of patients to 0.12 mg/kg in the third and final cohort of patients.
Item 9.01: Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit
Number
|
|
Description
|
| 104 | Inline XBRL for the cover page of this Current Report on Form 8-K. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
GENPREX, INC.
|
|||
|
Date: December 16, 2022
|
By:
|
/s/ Ryan Confer
|
|
|
Ryan Confer
|
|||
|
Chief Financial Officer
(Principal Financial Officer)
|
|||